Cantor Fitzgerald Maintains Overweight on Novo Nordisk, Raises Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has maintained an Overweight rating on Novo Nordisk (NVO) and increased the price target from $140 to $160.
March 08, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Novo Nordisk and raised the price target from $140 to $160.
The increase in price target by Cantor Fitzgerald reflects a positive outlook on Novo Nordisk's future performance. This endorsement from a reputable analyst is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100